Advertisement

Medical Oncology

, 32:209 | Cite as

The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas

  • Guohua Ren
  • Lijun Sheng
  • Haibo Liu
  • Yahong Sun
  • Yuji An
  • Yan LiEmail author
Original Paper

Abstract

In recent years, transforming growth factor-β (TGF-β) and the serine–arginine protein kinase 1 (SRPK1) have been recommended as a key signal mediator that is involved in oncogenesis. However, the mechanisms underlying TGF-β–SRPK1 pathway-mediated proliferation and apoptosis in the esophageal squamous cell carcinomas (ESCC) have not been well featured till now. We used immunohistochemistry, immunoblotting, and RT-PCR to assess the expression of SRPK1 in 120 cases of ESCC samples and cell lines. Subsequently, some in vitro assays were also applied where cells were administrated with TGF-β. We found that SRPK1 was highly expressed in ESCC tissues and acts as an independent prognostic factor for ESCC patients. In vitro studies indicated that overexpression of wild-type SRPK1 promoted ESCC cell proliferation, while overexpression of the kinase-dead mutant of SRPK1 or RNA interference against SRPK1 suppressed cell growth and enhanced apoptosis. The knockdown of SRPK1 also inhibited subcutaneous xenografts’ growth of ESCC cells in nude mice. Furthermore, Western bolt analysis showed SRPK1 can activate Akt phosphorylation and inhibit JNK phosphorylation. In conclusion, SRPK1 mediates TGF-β-induced proliferation and apoptosis by regulating AKT and JNK in ESCC, which indicates TGF-β–SRPK1 pathway may be suggested as a useful target to affect the progression of ESCC.

Keywords

SRPK1 TGF-β Proliferation Apoptosis ESCC 

Notes

Acknowledgments

We greatly thank other members in our laboratory for valuable suggestions and writing.

Conflict of interest

None.

References

  1. 1.
    Jemal A, Siegel R, Xu J. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoshino M, Fukui H, Ono Y, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology. 2007;74:15–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, Guo H, Yu C. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma. 2015;62(3):432–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Keshwani MM, Aubol BE, Fattet L, Ma CT, Qiu J, Jennings PA, Fu XD, Adams JA. Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function. Biochem J. 2015;466(2):311–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Lin JC, Lin CY, Tarn WY, Li FY. Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events. RNA. 2014;20(10):1621–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014;111(3):477–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Aubol BE, Adams JA. Recruiting a silent partner for activation of the protein kinase SRPK1. Biochemistry. 2014;53(28):4625–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, Sun C, Xia G. Periostin mediates TGF-β-Induced epithelial mesenchymal Transition in prostate cancer cells. Cell Physiol Biochem. 2015;36(2):799–809.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen Y, He Q, Yu C, Zhang S, Zhang C, Jia W. TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol Res. 2015;48(1):26.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou B, Li Y, Deng Q, Wang H, Wang Y, Cai B, Han ZG. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol Cell Biochem. 2013;379(1–2):191–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Toker A, Chin YR. Akt-ing up on SRPK1: oncogene or tumor suppressor? Mol Cell. 2014;54(3):329–30.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans. 2012;40(4):831–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Guohua Ren
    • 1
    • 2
  • Lijun Sheng
    • 3
  • Haibo Liu
    • 4
  • Yahong Sun
    • 2
  • Yuji An
    • 3
  • Yan Li
    • 1
    Email author
  1. 1.Department of Oncology, Qianfoshan HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of OncologyShandong Cancer HospitalJinanPeople’s Republic of China
  3. 3.Department of OncologyAffiliated Hospital of Shandong Academy of Medical SciencesJinanPeople’s Republic of China
  4. 4.Department of Thoracic Surgery, Jinan Central HospitalShandong UniversityJinanPeople’s Republic of China

Personalised recommendations